S100A4 inhibitor “Minnetamide” for prostate cancer treatment

Technology No. 2020-242
IP Status: Provisional Patent Application Filed; Application #: 63/037,355


  • Prostate cancer treatment

Technology Overview

Current treatments for prostate cancers (PC) are highly variable in their efficacy, particularly in the case of aggressive forms of cancers such as neuroendocrine type PC (NEPC). The technology is a small molecule (called “S100A-Minnetamide”) that inhibits a novel drug target, S100 calcium-binding protein A4 (S100A4). In animal models of disease, S100A-Minnetamide is well tolerated, bioavailable and results in reduced cancer growth

Phase of Development

In vitro and in vivo/animal studies completed.

Mohammad Saleem Bhat, PhD
Associate Professor, Dept. of Urology
External Link (www.cancer.umn.edu)


Desired Partnerships

This technology is now available for:

  • License
  • Sponsored research
  • Co-development
Please contact us to share your business’ needs and learn more.

  • swap_vertical_circlecloud_downloadSupporting documents (0)
Questions about this technology?